Dr. Lea Watson covers two drugs, Nuplazid and the new one  approved by the FDA, Aducanumab. Followed by Dr. Sing Palat, CMD and new President of CMDA who discusses the use of oxygen with nocturnal hypoxemia in COPD.
Recording Date: 5/6/2021
Available Credit
0.25 CMD-Clinical

Dr. Lea Watson covers two drugs, Nuplazid and the new one approved by the FDA, Aducanumab. Followed by Dr. Sing Palat, CMD and new President of CMDA who discusses the use of oxygen with nocturnal hypoxemia in COPD. Recording Date: 5/6/2021 Available Credit 0.25 CMD-Clinical

Dr. Lea Watson covers two drugs, Nuplazid and the new one&nbsp; approved by the FDA, Aducanumab. Followed by Dr. Sing Palat, CMD and new President of CMDA who discusses the use of oxygen with nocturnal hypoxemia in COPD.
Recording Date:&nbsp;5/6/2021
Available Credit
0.25 CMD-Clinical

CMDA | Aducanumab

Effective August 13, 2024, AMDA On-The-Go and all affiliate podcasts will now go by PALTtalk.

Explore the field of post-acute and long-term care, with expert interviews, journal article reviews, innovations news, and more. 

Statements made by guests on this podcast are their own opinions and are not necessarily the positions of the assocation. Speakers’ appearance on the program does not imply an endorsement of them, their views, or any entity they represent.

Education

Effective August 13, 2024, AMDA On-The-Go and all affiliate podcasts will now go by PALTtalk. Explore the field of post-acute and long-term care, with expert interviews, journal article reviews, innovations news, and more. Statements made by guests on this podcast are their own opinions and are not necessarily the positions of the assocation. Speakers’ appearance on the program does not imply an endorsement of them, their views, or any entity they represent.

Share CMDA | Aducanumab

Sign up to save your podcasts

CMDA | Aducanumab

CMDA | Aducanumab